Great satisfaction, complementary purchases planned.
Extract from the guestbook quesionnaire
The European Respiratory Society (ERS), organized its 29th congress from 28 September to 02 October 2019 in Madrid, Spain. Showcasing the excellence of respiratory medicine, it is an essential event for all pneumology professionals and the patient associations concerned. It brings together more than 15,000 doctors, scientists and other specialists in respiratory medicine (research laboratories, etc.).
This event promotes scientific research and provides access to educational resources on diseases such as asthma, the heart of the Optimhal-Protecsom laboratory.
The Optimhal-Protecsom laboratory actively participated in this knowledge sharing by presenting its latest research on several inhalation chambers for mechanical ventilation circuits, including Combihaler.
Combihaler® is an inhalation chamber for mechanical ventilation systems. It allows for the simultaneous administration of metered-dose drugs and a mesh nebulizer.
In this study, the in vitro performances of several spacers, including CombiHaler®, were evaluated for drug delivery with pressurized metered dose inhaler (pMDI) and vibrating mesh nebulizer, in comparison with T adapters usually used, in an adult mechanical ventilation model.
Results showed that in vitro drug delivery is higher when using a spacer instead of T pieces, with both a pMDI and a vibrating mesh nebulizer.
CombiHaler has similar or higher in vitro performances than other spacers and permits the use of both a pMDI and a vibrating mesh nebulizer without dismantling the breathing circuit : these are new successful results which strengthen our goals and our purpose of continuous improvement.
Each year, the Optimhal-Protecsom laboratory invests more than 25% of its turnover in research. This is an essential point for designing tomorrow’s medical devices with a constant goal : to improve the quality of life of patients and facilitate the work of caregivers.
In autumn, all the conditions are met to promote the proliferation of dust mites: heated housing, less airy, closed windows and reduced light are all factors that contribute to the concentration of allergenic particles in your indoor environment.
More than 3 in 10 French people suffer from allergy to dust mites and many people ignore it or minimize its consequences.
Among the 35% of French people who say they are allergic, 1 in 2 people considers that it is not a “real” disease and is thus exposed to a sometimes very serious evolution of their allergic disease. Asthma has an allergic origin for 80% of children and 50% of adults.
Respiratory illness is not to be taken lightly!
The association Asthme & Allergies calls, through an information and awareness campaign, patients and parents of allergic children to mobilize to better and faster detect allergy to dust mites in order to avoid these evolutions to asthma or other severe pathologies.
The Protecsom Laboratory, a specialist in allergen protection and improvement of the quality of life of patients, actively participates in this new awareness campaign of the association Asthma & Allergies, with several other partners and actors in the fight against mite allergy.
A 100% digital campaign !
This awareness campaign is deployed in the media and on social networks.
Discover four videos that feature the different symptoms of mite allergy (Eternity, Difficult Awakening, Runny Nose, etc.) and a page to answer all questions related to mite allergy. (Symptoms, Solutions and Risks).
A game created by the association Asthma & Allergy may also allow you to gain your protection. Be vigilant !